GWP.L Share News (GWP)

Jazz Pharmaceuticals to buy GW Pharmaceuticals for $7.2bn

(Sharecast News) - Jazz Pharmaceuticals has agreed to buy GW Pharmaceuticals for $7.2bn.

GW Pharmaceuticals stock flies 4.8% after reporting positive test trial

(Sharecast News) - GW Pharmaceuticals stock rose by 4.8% on Monday after it announced positive test results from new cannabis-based drug trials.

Sunday newspaper round-up: Inflation, RBS, Brexit defeat, BAE Systems

(ShareCast News) - Higher food and fuel prices drove inflation to a three-year zenith of 2% in January, up from 1.6% in December, with more increases coming as the year progresses. Figures from the Office for National Statistics are expected to confirm the jump in inflation this week, the Sunday Tel

DIRECTOR DEALINGS: GW Pharmaceuticals Chairman Sells 300,000 Shares

GW Pharmaceuticals to cancel London listing, keep Nasdaq

(ShareCast News) - GW Pharmaceuticals plans to cancel its shares from trading on AIM on 5 December, with the last day of trading on the 2nd, but will keep its listing on the Nasdaq, where most of its shares are held and traded. The biopharmaceutical company said it will continue to be headquartered

UPDATE 1-Third win for cannabis drug in epilepsy sends GW to record high

* Epidiolex cuts seizures in latest LGS clinical study * GW expects to file for U.S. approval in first half 2017 * Reuters previously reported GW received bid interest (Adds analyst comment and further details, updates shares) By Natalie Grover and Ben Hirschler Sept 26

GW Pharmaceuticals nears US new drug application for epilepsy drug

(ShareCast News) - GW Pharmaceuticals said it planned to apply to market its cannabis-derived treatment for childhood-onset epilepsy early next year after the drug produced strong results from its late-stage clinical trail. Epidiolex, the investigational cannabidiol medicine developed by GW, generat

DIRECTOR DEALINGS: GW Pharmaceuticals Medical Officer Sells Shares

EXCLUSIVE-GW Pharmaceuticals hires investment bank following approaches - sources

(Adds share reaction, background on the company) By Carl O'Donnell and Arno Schuetze Sept 7 (Reuters) - GW Pharmaceuticals Plc, a developer of marijuana-based epilepsy treatments, is working with an investment bank after other drugmakers approached it to express interest in an acquisi

UPDATE 2-U.S. agency denies petition to reclassify marijuana

(Adds background, research details, congressman, industry comment) By Doina Chiacu and Bill Berkrot WASHINGTON/NEW YORK, Aug 11 (Reuters) - The U.S. Drug Enforcement Administration on Thursday denied requests to stop classifying marijuana as a dangerous drug with no medical use, leavi

GW Pharmaceuticals widens loss as testing ramps up

(ShareCast News) - Cannabinoid-focused pharmaceutical company GW Pharmaceuticals posted financial results for the third quarter ended 30 June on Tuesday. The AIM-traded company reported a loss for the nine months of £46.7m, compared to £32.3m for the nine months ended 30 June 2015. It said the incr

UK GDP growth slumps to half previous rate, NIESR data shows

(ShareCast News) - UK economic growth halved in the last three months, according to analysis by a respected independent think tank, which is worse than the market expected and adds credence to predictions that the economy will contract in the third quarter and then fall into recession. Based on its

GW Pharmaceuticals Closes US Public Offering, Raising USD289.8 Million (ALLISS)

GW Pharmaceuticals keen on $150m US offering

(ShareCast News) - Developer of cannabinoid therapies GW Pharmaceuticals announced on Wednesday that it intends to sell, subject to market and other conditions, $150m of American Depositary Shares representing ordinary shares of GW on the NASDAQ Global Market, in an underwritten US public offering.

GW Pharmaceuticals Prices ADS Offering, Raising USD252 Million (ALLISS)